The IMpassion130 trial was a global, randomised, double-blind, phase III study of atezolizumab+nab-paclitaxel versus placebo+nab-paclitaxel in patients with treatment naive locally advanced or metastatic triple-negative breast cancer. Here, progression-free survival was statistically significantly longer in patients treated with the combination of atezolizumab+nab-paclitaxel compared with placebo+nab-paclitaxel. The side effect profile was favourable as no unexpected toxicities were observed in the intervention compared with the control arm. In the current podcast, PS provides insight on the response rate and the preliminary survival analysis of IMpassion130. Further possible biomarkers and the impact of the results on the treatment standard in breast cancer are discussed.
Authors: Heidi M Haikala; Johanna M Anttila; Elsa Marques; Tiina Raatikainen; Mette Ilander; Henna Hakanen; Hanna Ala-Hongisto; Mariel Savelius; Diego Balboa; Bjoern Von Eyss; Vilja Eskelinen; Pauliina Munne; Anni I Nieminen; Timo Otonkoski; Julia Schüler; Teemu D Laajala; Tero Aittokallio; Harri Sihto; Johanna Mattson; Päivi Heikkilä; Marjut Leidenius; Heikki Joensuu; Satu Mustjoki; Panu Kovanen; Martin Eilers; Joel D Leverson; Juha Klefström Journal: Nat Commun Date: 2019-02-06 Impact factor: 14.919